Thyroid Eye Disease — A Systemic & Endocrine Perspective

Overview

Thyroid eye disease (TED), also called Graves ophthalmopathy or thyroid-associated orbitopathy, is the most common cause of both unilateral and bilateral proptosis in adults. It's tempting to think of it as a straightforward downstream effect of hyperthyroidism — excess circulating thyroid hormone somehow "leaking into" the orbit — but that model doesn't hold up. TED is an extrathyroidal manifestation of the same autoimmune process that causes Graves disease, not a complication of the hormone excess itself. The eye findings can appear before the thyroid abnormality is ever detected, after it's already been treated and normalized, or even in patients who are biochemically euthyroid or hypothyroid. The unifying thread isn't hormone level — it's an autoantibody that happens to activate receptors in two different tissues, the thyroid gland and the orbit, largely independently of one another.

That reframing matters clinically. A patient whose Graves hyperthyroidism is well controlled on antithyroid medication can still have active, progressive orbital disease, and normalizing thyroid function tests alone does not reliably halt TED's course. The orbit, in a very real sense, runs its own autoimmune timeline once the underlying fibroblast population has been activated — which is why understanding TED requires understanding the orbital fibroblast itself, not just the thyroid axis that first drew attention to it.

Pathophysiology

Graves disease is caused by thyroid-stimulating immunoglobulins (TSIs) — autoantibodies, also referred to as TRAb (thyrotropin receptor antibodies), that bind the TSH receptor on thyroid follicular cells not as blockers but as agonists. They mimic TSH itself, driving unregulated hormone synthesis and glandular hyperplasia independent of the pituitary's normal negative-feedback control. Graves disease is the most common cause of hyperthyroidism in iodine-sufficient regions, shows a strong female predominance (roughly 7–8:1), typically peaks in the third to fourth decade of life, and in Caucasian populations is most strongly associated with the HLA-DR3 haplotype.

The orbital connection comes from where else the TSH receptor is expressed. Orbital fibroblasts co-express both the TSH receptor and the insulin-like growth factor-1 receptor (IGF-1R), and the two form a functional signaling complex on the fibroblast surface. Autoantibody cross-reactivity at this complex — the same antibodies capable of stimulating the thyroid's TSH receptor also engaging this orbital complex — triggers fibroblast proliferation and drives the overproduction of glycosaminoglycans, chiefly hyaluronic acid (hyaluronan). Hyaluronan is intensely hydrophilic: it draws water into the surrounding orbital connective tissue and extraocular muscles, and that osmotic swelling is the direct mechanism behind the soft-tissue edema, muscle enlargement, and eventual proptosis characteristic of TED. This TSHR/IGF-1R signaling complex is also why teprotumumab, an IGF-1R-blocking antibody, works as a targeted therapy — it interrupts this specific pathway rather than treating the thyroid gland at all.

Among environmental factors, cigarette smoking is the single strongest known modifiable risk factor for both developing TED and for it running a more severe course once present. Smoking cessation counseling is accordingly a core part of managing any Graves patient with orbital involvement, independent of whatever other therapy is chosen.

Clinical Features

Eyelid Signs

Upper eyelid retraction — Dalrymple sign, visible sclera above the superior limbus with the eye in primary gaze — is usually the earliest and most common physical sign of TED, present in up to 90% of patients, and it frequently precedes any noticeable proptosis or motility restriction. It results from two additive mechanisms: sympathetic overstimulation of Müller's muscle (which shares the eyelid-elevating job with the levator) and fibrosis/inflammatory infiltration of the levator complex itself. Because retraction can appear well before mechanical orbital changes do, its presence alone should not be read as proof of active proptosis or muscle disease — it's a distinct, earlier finding.

Von Graefe sign — lagging of the upper eyelid behind the globe on downgaze, so the lid fails to fall smoothly with the eye — is a related but separate finding from Dalrymple sign, reflecting the same levator/Müller's muscle overactivity and fibrosis but specifically demonstrated during ocular movement rather than in primary position.

Extraocular Muscle Involvement

Of the extraocular muscles, the inferior rectus is the one most frequently and most severely affected by TED's inflammatory infiltration and subsequent fibrosis. A fibrotic, non-compliant inferior rectus tethers the globe and restricts elevation, producing a restrictive hypotropia with characteristic difficulty looking up — a pattern that can be mistaken for a superior rectus or cranial nerve palsy if the restrictive nature of the limitation (rather than a true weakness) isn't recognized on forced duction testing.

On CT or MRI, TED classically produces fusiform enlargement of the extraocular muscle bellies with sparing of the tendinous insertions. This tendon-sparing pattern is the key radiographic differentiator from orbital myositis, an inflammatory condition that frequently does involve the tendon and can otherwise mimic TED's muscle enlargement on imaging alone. Treating a case as ordinary TED myopathy without checking tendon involvement risks missing myositis or another orbital inflammatory process that calls for a different workup and treatment approach.

Compressive Optic Neuropathy

Dysthyroid (compressive) optic neuropathy is TED's vision-threatening complication: the enlarged, fibrotic extraocular muscles — especially at the crowded orbital apex, where several muscles converge around the optic nerve — compress the nerve directly. This is a distinct mechanism from ischemic optic neuropathy, demyelinating optic neuritis, or Foster Kennedy syndrome, and it should be considered in any TED patient with unexplained decreased visual acuity, color desaturation, or a relative afferent pupillary defect, even if proptosis itself looks unremarkable — apical crowding can compress the nerve without dramatic globe displacement.

Diagnosis / Workup

The biochemical picture in untreated Graves disease is a suppressed TSH with an elevated free T4, reflecting excess circulating hormone shutting down pituitary TSH release via negative feedback. An intermediate pattern — suppressed TSH with normal free T4 and T3 — defines subclinical hyperthyroidism, which often precedes overt biochemical hyperthyroidism and is worth recognizing in a patient with early orbital signs but seemingly normal thyroid hormone levels.

Hashimoto thyroiditis, the other major autoimmune thyroid disease, works by the opposite mechanism: lymphocytic infiltration and antibodies against thyroid peroxidase and thyroglobulin gradually destroy the gland rather than stimulating it, producing hypothyroidism instead of hyperthyroidism. Anti-thyroid peroxidase (anti-TPO) antibodies are present in the majority of Hashimoto patients and are a useful serologic distinguisher from Graves disease, though it's worth remembering that worldwide, iodine deficiency — not Hashimoto's — remains the most common overall cause of hypothyroidism; Hashimoto's is the leading cause specifically in iodine-sufficient regions such as the United States.

Orbital imaging (CT or MRI) supports the diagnosis and specifically helps exclude mimickers: fusiform, tendon-sparing extraocular muscle enlargement supports TED, while tendon involvement should raise suspicion for orbital myositis or another orbital inflammatory process instead.

Management

Acute compressive optic neuropathy is an emergency within TED and is treated first-line with high-dose intravenous corticosteroids (pulsed IV methylprednisolone) to rapidly reduce orbital inflammation and apical crowding. Urgent orbital decompression surgery is reserved for patients who fail to respond promptly to IV steroids — it is not the first-line intervention, but the necessary next step when medical therapy doesn't relieve the compression quickly enough to protect vision.

For active moderate-to-severe TED more broadly — not restricted to the optic neuropathy emergency above — teprotumumab (brand name Tepezza) is an approved, targeted therapy. As an IGF-1 receptor-inhibiting monoclonal antibody, it directly blocks the IGF-1R half of the TSHR/IGF-1R signaling complex described above, interrupting the orbital fibroblast activation that drives glycosaminoglycan production and soft-tissue expansion. Pivotal trials demonstrated meaningful reductions in both proptosis and inflammatory activity, making it the first therapy aimed at TED's actual orbital mechanism rather than only its downstream thyroid trigger or its inflammatory consequences.

Related Topics

Continue exploring Systemic Disease & the Eye: